Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Hai-Yan Tu"'
Autor:
Wei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, Zhi-Hong Chen, Yi-Chen Zhang, Ming-Yi Yang, Jia-Qi Liu, Jing-Yan Xu, Xiao-Rong Yang, Ri-Wei Zhong, Li-Bo Tang, Lin-Xi Yin, Yu Deng, Ying-Long Peng, Chang Lu, Bao-Long Chen, Dong-Xian Ke, Hai-Yan Tu, Jin-Ji Yang, Chong-Rui Xu, Yi-Long Wu, Qing Zhou
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background The effects of gut microbiota and metabolites on the responses to immune checkpoint inhibitors (ICIs) in advanced epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC) have been studied. However, the
Externí odkaz:
https://doaj.org/article/09696509dfd34aa9a776fab02e6b047a
Autor:
Yang-Si Li, Wen-Pu Lai, Kai Yin, Mei-Mei Zheng, Hai-Yan Tu, Wei-Bang Guo, Liang Li, Shou-Heng Lin, Zhen Wang, Lu Zeng, Ben-Yuan Jiang, Zhi-Hong Chen, Qing Zhou, Xu-Chao Zhang, Jin-Ji Yang, Wen-Zhao Zhong, Xue-Ning Yang, Bin-Chao Wang, Yi Pan, Hua-Jun Chen, Fa-Man Xiao, Hao Sun, Yue-Li Sun, Xiao-Yan Bai, E.-E. Ke, Jia-Xin Lin, Si-Yang Maggie Liu, Yangqiu Li, Oscar Junhong Luo, Yi-Long Wu
Publikováno v:
Cell Reports, Vol 43, Iss 8, Pp 114613- (2024)
Summary: Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance. We conducted single-cell RNA sequencing on cerebrospinal fluid (CSF) from EGFR-mutant NSC
Externí odkaz:
https://doaj.org/article/0665f6377f1241e58a85cf57da13bbbc
Autor:
Yi‐Long Wu, Shun Lu, Ying Cheng, Qing Zhou, Hai‐Yan Tu, Qing‐Hua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, Shao‐Kun Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, An‐Wen Liu, Xu‐Chao Zhang, Hui Li, Rong‐Rong Chen, Dong‐Mei Lin, Cong‐Ying Xie, Zheng‐Fei Zhu, Hui‐Ying Liang, Yong Song, Xiao‐Rong Dong, Ming‐Fang Zhao, Gui‐Bin Qiao, Jiu‐Wei Cui, Zi‐Ming Li, Zhi‐Jie Wang, Xiao‐Yuan Chen, Nong Yang, Gen Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, Jian‐Chun Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Qi‐Tao Yu, Li‐Feng Wang, Hai‐Bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui‐Juan Wang, Fang Wu, Wen‐Zhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Fan Yang, Qun Wang, Dong‐Sheng Yue, Jian‐Ya Zhou, Peng Shen, Jia‐Tao Zhang, Xiao‐Long Yan, Mei‐Juan Huang, Wei‐Neng Feng, Li Li, Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)
Publikováno v:
Medicine Advances, Vol 1, Iss 4, Pp 293-305 (2023)
Abstract The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challeng
Externí odkaz:
https://doaj.org/article/6cf86ef452334af4a74e37fd66750545
Autor:
Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, Si-Yang Maggie Liu, Wen-Zhao Zhong, Yi-Long Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab–chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical sta
Externí odkaz:
https://doaj.org/article/fac0f07d3dc04d809e388bf7352818af
Autor:
Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Publikováno v:
Molecular Oncology, Vol 17, Iss 8, Pp 1581-1594 (2023)
The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institu
Externí odkaz:
https://doaj.org/article/d5aadd22e14b45079cd59c661d0f474c
Autor:
Yuanbin Cui, Tingjie Yuan, Ying Wang, Diwei Zheng, Le Qin, Shanglin Li, Zhiwu Jiang, Shouheng Lin, Wenjing Guo, Zhi Wang, Zhaoduan Liang, Yi Li, Yao Yao, Xingguo Liu, Qiannan Tang, Hai-Yan Tu, Xu-Chao Zhang, Zhaoyang Tang, Nathalie Wong, Zhenfeng Zhang, Dajiang Qin, Jean Paul Thiery, Kailin Xu, Peng Li
Publikováno v:
Cell Reports, Vol 42, Iss 7, Pp 112797- (2023)
Summary: Chimeric antigen receptor (CAR) T cell therapy lacks persistent efficacy with “on-target, off-tumor” toxicities for treating solid tumors. Thus, an antibody-guided switchable CAR vector, the chimeric Fc receptor CD64 (CFR64), composed of
Externí odkaz:
https://doaj.org/article/19026a5a9b9f441696fdcf97f3be7fbe
Autor:
Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, Xue Fan, Chong-Rui Xu, Zhi-Hong Chen, Fen Wang, Xiao-Rong Yang, Jia-Yi Deng, Ming-Yi Yang, Qing Gou, Shi-Qi Mei, Wei-Chi Luo, Ri-Wei Zhong, Wen-Zhao Zhong, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Yi-Long Wu, Qing Zhou
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTMetabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying the association between metabolic phenotypes and immune cells in lung adenocarcinoma (LUAD) may reveal mechanisms of resi
Externí odkaz:
https://doaj.org/article/69ff1c8e561c44988808d82daaa7d78f
Autor:
Kai‐Cheng Peng, Jun‐Wei Su, Zhi Xie, Han‐Min Wang, Mei‐Mei Fang, Wen‐Feng Li, Yu‐Qing Chen, Xu‐Hui Guan, Jian Su, Hong‐Hong Yan, Xu‐Chao Zhang, Hai‐Yan Tu, Qing Zhou, Hua‐Jun Chen, Yi‐Long Wu, Jin‐Ji Yang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 11, Pp 1619-1630 (2022)
Abstract Background MET dysregulation has been implicated in the development of primary and secondary resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. However, the clinicopathological characteristics and outcomes of patients harboring EGFR
Externí odkaz:
https://doaj.org/article/82192f83a6d54e8a9200d4bcfce4e18f
Autor:
Zhen Wang, Xu-Chao Zhang, Wei-Neng Feng, Li Zhang, Xiao-Qing Liu, Wei-Bang Guo, Yan-Ming Deng, Qing-Feng Zou, Jin-Ji Yang, Qing Zhou, Bin-Chao Wang, Hua-Jun Chen, Hai-Yan Tu, Hong-Hong Yan, Yi-Long Wu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Circulating tumor cells (CTCs) are prognostic biomarker in non-small-cell lung cancer (NSCLC). CTCs could also be used as predictor of efficacy of systemic treatments in advanced NSCLC. Objectives: We described the dynamic changes of CTCs
Externí odkaz:
https://doaj.org/article/3d41e67e02a8435983d78956b0f52623
Autor:
Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms to osimertinib and investigate subsequen
Externí odkaz:
https://doaj.org/article/ff49dc0b1e09455f9e43b69ece66e951